Lantern Pharma Reports First Complete Response in Phase 1 LP-284 Trial for Aggressive DLBCL
July 23rd, 2025 1:46 PM
By: Newsworthy Staff
Lantern Pharma's LP-284 shows promising results in a Phase 1 trial, offering hope for patients with aggressive DLBCL who have failed prior treatments.
Lantern Pharma (NASDAQ: LTRN) has reported a significant milestone in its ongoing Phase 1 trial of LP-284, with a heavily pretreated patient achieving a complete metabolic response. This patient, suffering from aggressive Grade 3 non-germinal center B-cell DLBCL, had not responded to three prior treatments, including CAR-T and bispecific antibody therapy, before showing improvement after just two cycles of LP-284. Developed using Lantern's RADR(R) AI platform, LP-284's success underscores its potential as a groundbreaking therapy for refractory lymphomas, positioning the company for accelerated development in the $4 billion global B-cell cancer market.
The achievement highlights the efficacy of LP-284's synthetic lethal mechanism and Lantern Pharma's innovative approach to oncology drug development. By leveraging AI and machine learning, the company has significantly reduced the time and cost associated with bringing new therapies to clinical trials, marking a potential shift in how cancer treatments are developed and delivered to patients in need.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
